Alendronate trial to reduce hidden HIV
Treatments studied
Part of Infections clinical trials.
This study tests if alendronate, a bone-strengthening medicine, can shrink the reservoir of HIV that stays in your body even when on treatment. You must have well-controlled HIV on antiretroviral therapy for at least one year but no more than ten years, and meet specific health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed HIV for at least 1 year and be on antiretroviral therapy (ART) for 1 to 10 years.
- Your viral load must be undetectable (below 50 copies/mL) for the last 48 weeks.
- Your CD4 count must be 350 or higher within the last month.
- You must be able to swallow pills and not have any major bone, stomach, or dental problems.
- You need certain lab results (like kidney function, vitamin D, and blood counts) within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a small protein called IL-15 can help your immune system keep HIV under control after pausing your daily HIV medications. You will stop your meds for a short time under careful monitoring, and the hope is that your body might learn to fight HIV without daily pills.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
This trial tests if zoledronic acid, a drug that strengthens bones, can prevent bone loss caused by starting HIV treatment. It is for people newly diagnosed with HIV who have not yet taken any HIV medication.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.